GlassScriptPhysician profile
Colleen Arrasmith
NPI 1215315387
$3,658.60
in general payments reported to CMS, 2019-2025
25 companies · $526 in 2025
The $526 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $929 · 2022: $1,067 · 2023: $667 · 2024: $469 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.77 | 2021-2025 | |
| Novo Nordisk INC | $787.87 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $464.94 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $320.97 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $166.49 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $163.41 | 2022-2024 | |
| Amarin Pharma, INC. | $115.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $99.56 | 2021-2025 | Lagevrio |
| Novartis Pharmaceuticals Corporation | $95.41 | 2022-2023 | |
| Astellas Pharma US INC | $81.77 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $77.69 | 2021-2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.02 | 2021-2023 | Jardiance, Synjardy |
| Pfizer INC. | $54.78 | 2021-2025 | |
| Exact Sciences Corporation | $53.36 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $51.63 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $45.16 | 2022-2023 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $39.29 | 2021 | |
| Inspire Medical Systems, INC. | $30.62 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $30.25 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.09 | 2023 | Strensiq |
| Boston Scientific Corporation | $23.54 | 2025 | Wavewriter Alpha Prime 16 |
| Corcept Therapeutics | $19.37 | 2025 | Korlym |
| Insulet Corporation | $18.16 | 2022 | |
| Eisai INC. | $17.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Arrasmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.